SCHEMBL7016574

SCHEMBL7016574

CC(C)COC(=O)Nc1c[c]ccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 4/20 0.49
HTT P42858 3/20 0.49
MAPK1 P28482 2/20 0.49
ALOX15 P16050 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HPGD P15428 1/20 0.44
MAOB P27338 1/20 0.42
KDM4E B2RXH2 3/20 0.41
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
MAPT P10636 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
CSNK2A2 P19784 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1419617 0.83 MAPK1 (0.54) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL27263579 0.82 SLC1A5 (0.42) ALDH1A1LMNASMN1; SMN2TSHRMAPK1
SCHEMBL8602983 0.81 LMNA (0.74) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL2533532 0.81 HPGD (0.57) ALDH1A1LMNASMN1; SMN2TSHRMAPK1
SCHEMBL2540830 0.80 HPGD (0.55) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL359677 0.79 SMN1; SMN2 (0.48) ALDH1A1LMNASMN1; SMN2HTTMAPK1
SCHEMBL4800127 0.78 RAB9A (0.59) ALDH1A1LMNASMN1; SMN2MAPK1L3MBTL1
SCHEMBL7015447 0.77 RAB9A (0.54) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL19748921 0.77 HDAC1 (0.43) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL7020328 0.77 TRPV1 (0.45) ALDH1A1LMNASMN1; SMN2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017223514-A9 LXR INVERSE AGONISTS FOR TREATMENT OF CANCER SAINT LOUIS UNIVERSITY (US) 2018-04-12 WO claimed
WO-2017223514-A1 LXR INVERSE AGONISTS FOR TREATMENT OF CANCER SAINT LOUIS UNIVERSITY (US) 2017-12-28 WO claimed
EP-0889034-B1 AMINOPYRIDINE DERIVATIVES BANYU PHARMA CO LTD (JP) 2003-09-17 EP disclosed
US-6011039-A USEFUL AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; TREATING HYPERPHAGIA, OBESITY OR DIABETES BANYU PHARMACEUTICAL CO., LTD. (JP) 2000-01-04 US disclosed
EP-0889034-A1 AMINOPYRIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-01-07 EP disclosed